0000899243-20-020691.txt : 20200729 0000899243-20-020691.hdr.sgml : 20200729 20200729214541 ACCESSION NUMBER: 0000899243-20-020691 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200728 FILED AS OF DATE: 20200729 DATE AS OF CHANGE: 20200729 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MPM BioVentures 2018 GP LLC CENTRAL INDEX KEY: 0001818701 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 201058918 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-425-9206 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MPM BioVentures 2018 LLC CENTRAL INDEX KEY: 0001818702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 201058919 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-425-9206 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MPM BioVentures 2014, L.P. CENTRAL INDEX KEY: 0001609492 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 201058920 BUSINESS ADDRESS: STREET 1: C/O MPM ASSET MANAGEMENT LLC STREET 2: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 425-9200 MAIL ADDRESS: STREET 1: C/O MPM ASSET MANAGEMENT LLC STREET 2: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: iTeos Therapeutics, Inc. CENTRAL INDEX KEY: 0001808865 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 857-204-4583 MAIL ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-28 0 0001808865 iTeos Therapeutics, Inc. ITOS 0001609492 MPM BioVentures 2014, L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001818702 MPM BioVentures 2018 LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001818701 MPM BioVentures 2018 GP LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 Common Stock 2020-07-28 4 C 0 1269230 A 1269230 I See Footnote Common Stock 2020-07-28 4 C 0 84655 A 84655 I See Footnote Common Stock 2020-07-28 4 C 0 43687 A 43687 I See Footnote Common Stock 2020-07-28 4 C 0 801619 A 801619 I See Footnote Common Stock 2020-07-28 4 C 0 42605 A 42605 I See Footnote Common Stock 2020-07-28 4 C 0 15820 A 15820 I See Footnote Common Stock 2020-07-28 4 C 0 724702 A 1993932 I See Footnote Common Stock 2020-07-28 4 C 0 48336 A 132991 I See Footnote Common Stock 2020-07-28 4 C 0 24944 A 68381 I See Footnote Common Stock 2020-07-28 4 C 0 457706 A 1259325 I See Footnote Common Stock 2020-07-28 4 C 0 24326 A 66931 I See Footnote Common Stock 2020-07-28 4 C 0 9033 A 24853 I See Footnote Common Stock 2020-07-28 4 P 0 89955 19.00 A 2083887 I See Footnote Common Stock 2020-07-28 4 P 0 5994 19.00 A 138985 I See Footnote Common Stock 2020-07-28 4 P 0 3096 19.00 A 71727 I See Footnote Common Stock 2020-07-28 4 P 0 56814 19.00 A 1316139 I See Footnote Common Stock 2020-07-28 4 P 0 3020 19.00 A 69951 I See Footnote Common Stock 2020-07-28 4 P 0 1121 19.00 A 25974 I See Footnote Series B Preferred Stock 2020-07-28 4 C 0 3824591 D Common Stock 1269230 0 I See Footnote Series B Preferred Stock 2020-07-28 4 C 0 255094 D Common Stock 84655 0 I See Footnote Series B Preferred Stock 2020-07-28 4 C 0 131645 D Common Stock 43687 0 I See Footnote Series B Preferred Stock 2020-07-28 4 C 0 2415530 D Common Stock 801619 0 I See Footnote Series B Preferred Stock 2020-07-28 4 C 0 128384 D Common Stock 42605 0 I See Footnote Series B Preferred Stock 2020-07-28 4 C 0 47674 D Common Stock 15820 0 I See Footnote Series B-2 Preferred Stock 2020-07-28 4 C 0 2361805 D Common Stock 724702 0 I See Footnote Series B-2 Preferred Stock 2020-07-28 4 C 0 157529 D Common Stock 48336 0 I See Footnote Series B-2 Preferred Stock 2020-07-28 4 C 0 81295 D Common Stock 24944 0 I See Footnote Series B-2 Preferred Stock 2020-07-28 4 C 0 1491666 D Common Stock 457706 0 I See Footnote Series B-2 Preferred Stock 2020-07-28 4 C 0 79281 D Common Stock 24326 0 I See Footnote Series B-2 Preferred Stock 2020-07-28 4 C 0 29440 D Common Stock 9033 0 I See Footnote Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. The shares of Series B Convertible Preferred stock held by MPM BioVentures 2014 LP ("BV 2014") will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM BioVentures 2014 (B) LP ("BV 2014(B)") will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM BioVentures 2018 LP ("BV 2018") will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering. (Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM BioVentures 2018 (B) LP ("BV 2018(B)") will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2014 will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2014(B) will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. (Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2018 will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by BV 2018(B) will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("2014 BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). Luke Evnin, Ansbert Gadicke and Todd Foley are the managing directors of 2014 BV LLC and members of MPM Asset Management Investors BV2014 LLC. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("2018 BV LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). Luke Evnin, Ansbert Gadicke, Todd Foley and Edward Hurwitz are the managing directors of 2018 BV LLC and members of MPM Asset Management Investors BV2018 LLC. Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein. On July 28, 2020, BV 2014 purchased 89,955 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. On July 28, 2020, BV 2014(B) purchased 5,994 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. On July 28, 2020, MPM Asset Management Investors BV 2014 LLC purchased 3,096 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. On July 28, 2020, BV 2018 purchased 56,814 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. On July 28, 2020, BV 2018(B) purchased 3,020 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. On July 28, 2020, MPM Asset Management Investors BV 2018 LLC purchased 1,121 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. Form 2 of 2. /s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC 2020-07-29 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC 2020-07-29